Search
Search Results
-
Delphi consensus for the third-line treatment of metastatic colorectal cancer
PurposeThe optimal drug regimen and sequence are still unknown for patients with metastatic colorectal cancer (mCRC) who are candidates for...
-
Virological outcomes of third-line antiretroviral therapy in a global context: a systematic reviews and meta-analysis
BackgroundDespite remarkable progress, HIV’s influence on global health remains firm, demanding continued attention. Understanding the effectiveness...
-
Nivolumab versus irinotecan as third- or later-line treatment for advanced gastric cancer: a multi-center retrospective study
BackgroundThe present study aimed to compare the efficacy and safety of nivolumab (NIVO) and irinotecan (IRI) and to identify clinical factors that...
-
Efficacy and Safety of Weekly Bortezomib-dexamethasone as the Third-Line Therapy for Warm Autoimmune Hemolytic Anemia: a Case Series of 5 Patients
BackgroundWarm autoimmune hemolytic anaemia (wAIHA) is a chronic condition. Despite the high initial responses seen with the first two treatment...
-
Anlotinib as a third-line or further treatment for recurrent or metastatic nasopharyngeal carcinoma: a single-arm, phase 2 clinical trial
BackgroundTreatment options beyond the first-line setting for recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) are limited. The role of the...
-
Current Treatment Landscape for Third- or Later-Line Therapy in Metastatic Colorectal Cancer
Purpose of ReviewThe aim of this paper is to summarize the current treatment landscape in metastatic colorectal cancer, as well as those on the...
-
A systematic review and meta-analysis assessing antiretroviral therapy for treatment-experienced HIV adult patients using an optimized background therapy approach: is there evidence enough for a standardized third-line strategy?
BackgroundThe World Health Organization (WHO) has identified the need for evidence on third-line antiretroviral therapy (ART) for adults living with...
-
Real-world efficacy and safety of anlotinib as third- or further-line treatment in refractory small cell lung cancer
PurposeAs a novel antiangiogenic multi-target tyrosine kinase inhibitor recently approved in China, anlotinib has exhibited promising anticancer...
-
Multi-drug-resistant chronic endometritis in infertile women with repeated implantation failure: trend over the decade and pilot study for third-line oral antibiotic treatment
PurposeTo evaluate the yearly prevalence and annual transition of multi-drug-resistant-chronic endometritis (MDR-CE) in infertile women with a...
-
Health economic analysis of third-line interventions in diffuse large B-cell lymphomas in Germany: applying the efficiency frontier
BackgroundIn the past decades, highly innovative treatments in the field of diffuse large B-cell lymphoma (DLBCL) became available in clinical...
-
Enhancing Third-Line Therapies for Overactive Bladder Using Patient Education Strategies
Purpose of ReviewIn this review, we discuss the current literature concerning the use of patient education interventions for the improvement of...
-
Assessing comprehension of online information in the United States for third-line treatment of overactive bladder
Introduction and hypothesisOveractive bladder (OAB) affects up to 43% of women. Treatment ranges from lifestyle modification to invasive therapies....
-
-
Prognostic significance of third-line treatment for patients with metastatic castration-resistant prostate cancer: comparative assessments between cabazitaxel and other agents
BackgroundCabazitaxel has played an important role in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC);...
-
Real-world effectiveness of third- or later-line treatment in Japanese patients with HER2-positive, unresectable, recurrent or metastatic gastric cancer: a retrospective observational study
BackgroundReal-world evidence on the preference for and effectiveness of third- or later-line (3L +) monotherapy for HER2-positive gastric cancer is...
-
Safety and efficacy of ICI plus anlotinib vs. anlotinib alone as third-line treatment in extensive-stage small cell lung cancer: a retrospective study
PurposeThe objective of this study was to evaluate the safety and efficacy of immune checkpoint inhibitor (ICI) plus anlotinib as third-line...
-
Real-World Cost Effectiveness of a Policy of KRAS Testing to Inform Cetuximab or Panitumumab for Third-Line Therapy of Metastatic Colorectal Cancer in British Columbia, Canada
BackgroundCetuximab and panitumumab, two anti-EGFR therapies, are widely used for third-line therapy of metastatic colorectal cancer (mCRC) with...
-
Cost-Effectiveness Analysis of Anlotinib as Third- or Further-Line Treatment for Relapsed Small Cell Lung Cancer (SCLC) in China
IntroductionThe survival of patients with relapsed small cell lung cancer (SCLC) has achieved little progress in the last several decades. ALTER1202...
-
Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup analysis of a randomized phase 2 study (ALTER1202)
Patients with small-cell lung cancer (SCLC) relapse within months after completing previous therapies. This study aimed to investigate the efficacy...